Drugs / Trazpiroben
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04831502 | Apr 2021 → Feb 2022 | — | Takeda | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT04454918 | Jul → Sep 2020 | — | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04121078 | Oct → Nov 2019 | — | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03849690 | Feb → Apr 2019 | — | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03237156 | Aug → Oct 2017 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT03161405 | Jun → Jul 2017 | — | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT03544229 | Oct 2018 → Jun 2021 | idiopathic gastroparesis | Millennium Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 2 | NCT03268941 | Sep 2017 → Mar 2018 | gastroparesis | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trazpiroben | “The pharmacokinetics of oral trazpiroben (TAK-906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study.” PMID 35460165 ↗ May 20223“Trazpiroben, a dopamine D2 /D3 receptor antagonist under development to treat gastroparesis, displays decreasing solubility with increasing pH.” PMID 35218604 ↗ Feb 2022 “Trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, is under development for chronic treatment of moderate-to-severe gastroparesis.” PMID 34148244 ↗ Jun 2021 “Trazpiroben (TAK-906) is a peripherally selective dopamine D2 /D3 receptor antagonist being developed to treat chronic gastroparesis.” PMID 34967147 ↗ Dec 2021 |
| Known as | TAK-906 | “Trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, is under development for chronic treatment of moderate-to-severe gastroparesis.” PMID 34148244 ↗ Jun 2021 |
| Action | Inhibit | “Trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, is under development for chronic treatment of moderate-to-severe gastroparesis.” PMID 34148244 ↗ Jun 2021 |
| Modality | Small molecule | — CHEMBL4650340 ↗ |
| Route | Oral | “Participants were given an oral dose of TAK-906 in the First Intervention Period” NCT03161405 ↗ |
| Target | DRD2 | “Dopamine D2 receptor antagonist” CHEMBL4650340 ↗ |
| Target | DRD3 | “Dopamine D3 receptor antagonist” CHEMBL4650340 ↗ |